The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Preclinical Data Supporting Use of CAR T-Cell Therapy in Multiple Myeloma

Noopur S. Raje, MD
Published Online:4:48 PM, Mon June 11, 2018

Noopur S. Raje, MD, a medical oncologist at Massachusetts General Hospital, discusses chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma. This therapy has been an exciting advancement in both hematology as well as solid tumors, she notes.

Research has been investigating the use of CAR T cells in combination with bb2121 and a lentiviral vector. This recognizes humanized BCMA, Raje explains. The addition of 4-1BB to this also helps with a slow and consistent expansion of the T cells, which also has less toxicity.

B-cell maturation antigen (BCMA) is a good target for multiple myeloma and has been studied preclinically for a while, Raje adds. It is an exciting development for this field. However, concerns with this type of targeted therapy include potential impacts on treatment due to high BCMA levels sometimes found in patients with multiple myeloma. Researchers also wonder whether BCMA receptor density will affect the treatment. Preclinical data does not support either of these concerns, though.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.